Bortezomib in the Treatment of Multiple Myeloma [recurso electrónico] / edited by Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson.
Tipo de material:
TextoSeries Milestones in Drug TherapyEditor: Basel : Springer Basel : Imprint: Springer, 2011Descripción: VIII, 179p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783764389482Tema(s): Medicine | Oncology | Toxicology | Cytology | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | ApoptosisFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 616.994 Clasificación LoC:RC254-282Recursos en línea: Libro electrónico
En: Springer eBooksResumen: Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
| Tipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
| Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | RC254 -282 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 377019-2001 |
Navegando Biblioteca Electrónica Estantes, Código de colección: Colección de Libros Electrónicos Cerrar el navegador de estanterías (Oculta el navegador de estanterías)
| RC254 -282 Pediatric Liver Tumors | RC254 -282 Induction Chemotherapy | RC254 -282 Pediatric Oncology | RC254 -282 Bortezomib in the Treatment of Multiple Myeloma | RC261 -271 Retroviruses and Insights into Cancer | RC261 -271 Molecularly Targeted Therapy for Childhood Cancer | RC261 -271 Modern Molecular Biology |
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
19
